Sienna Biopharma: Surges as hair removal solution meets study goal

Sienna Biopharmaceuticals

08/02/2019 15:56

** Shares of drug developer  SNNA.O  surge as much as 28.5 
pct to $3.47
    ** Co says its experimental hair removal solution, SNA-001,
in combination with common laser system, met the main goal of
non-inferiority in hair reduction compared with placebo in a
pivotal study  urn:newsml:reuters.com:*:nGNX2smqZD
    ** If cleared, SNA-001 has potential to expand the $3 bln
U.S. laser hair removal market as an effective option for
light-haired consumers - SNNA
    ** SNNA says the co will seek strategic partnership to
develop SNA-001, which is also being tested for acne
    ** Up to Thursday's close, SNNA had climbed 16.4 pct this
year

 (Reporting by Manogna Maddipatla)
 ((Reuters Messaging:
manojna.kalyani.thomsonreuters.com@reuters.net))